Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al

被引：3
|
作者：
Berkhout, Lea C. [1 ]
l'Ami, Merel J. [2 ]
Wolbink, Gerrit Jan [1 ,2 ]
Rispens, Theo [1 ]
机构：
[1] Sanquin Res, Immunopathol, Amsterdam, Netherlands
[2] Amsterdam Rheumatol & Immunol Ctr, Reade, Amsterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷 / 11期
关键词：
anti-TNF; disease activity; rheumatoid arthritis; TNF-alpha; treatment;
D O I：
10.1136/annrheumdis-2019-216557
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 42 条
  • [31] Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial
    Bouman, Chantal A. M.
    van Herwaarden, Noortje
    van den Hoogen, Frank H. J.
    Fransen, Jaap
    van Vollenhoven, Ronald F.
    Bijlsma, Johannes W. J.
    van der Maas, Aatke
    den Broeder, Alfons A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (10) : 1716 - 1722
  • [32] Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II) Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
    Shimizu, Toshimasa
    Kawashiri, Shin-Ya
    Sato, Shuntaro
    Morimoto, Shimpei
    Minoda, Shuri
    Kawazoe, Yurika
    Kuroda, Shohei
    Tashiro, Shigeki
    Sumiyoshi, Remi
    Hosogaya, Naoki
    Yamamoto, Hiroshi
    Kawakami, Atsushi
    MEDICINE, 2020, 99 (32) : E21480
  • [33] Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: A retrospective, multi-center descriptive study: Comment on the article by Nakano K et al.
    Urata, Yukitomo
    MODERN RHEUMATOLOGY, 2023, 33 (03) : 631 - 631
  • [34] Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial
    Almayali, Abdullah Ali Hadi
    Boers, Maarten
    Hartman, Linda
    Opris, Daniela
    Bos, Reinhard
    Kok, Marc R.
    Da Silva, Jose A. P.
    Griep, Ed
    Klaasen, Ruth
    Allaart, Cornelia F.
    Baudoin, Paul
    Raterman, Hennie G.
    Szekanecz, Zoltan
    Buttgereit, Frank
    Masaryk, Pavol
    Lems, Willem
    Smulders, Yvo
    Cutolo, Maurizio
    ter Wee, Marieke M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (10) : 1307 - 1314
  • [35] TREAT TO TARGET STRATEGY PLUS CERTOLIZUMAB IN COMPARISON TO CONTINUED, FIXED CSDMARD PLUS CORTICOSTEROIDS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS (REMISSION BY INTRA-ARTICULAR INJECTION PLUS CERTOLIZUMAB, THE RICE STUDY): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL
    Mueller, R.
    Spaeth, M.
    von Restorff, C.
    Ackermann, C.
    von Kempis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 613 - 613
  • [36] Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
    Ruscitti, Piero
    Berardicurti, Onorina
    Cipriani, Paola
    Giacomelli, Roberto
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [37] Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Ishiguro, Naoki
    Yamanaka, Hisashi
    Yoneda, Toshiyuki
    Ohira, Takeshi
    Okubo, Naoki
    Genant, Harry K.
    van der Heijde, Desiree
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (06) : 983 - 990
  • [38] Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA)
    Emery, Paul
    Burmester, Gerd R.
    Naredo, Esperanza
    Zhou, Yijie
    Hojnik, Maja
    Conaghan, Philip G.
    BMJ OPEN, 2018, 8 (02):
  • [39] Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. (vol 374, pg 210, 2009)
    Smolen, J. S.
    Kay, J.
    Doyle, M. K.
    LANCET, 2009, 374 (9699): : 1422 - 1422
  • [40] Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA)
    De Meyst, Elias
    Bertrand, Delphine
    Joly, Johan
    Doumen, Michael
    Marchal, Anja
    Thelissen, Marc
    Neerinckx, Barbara
    Westhovens, Rene
    Verschueren, Patrick
    TRIALS, 2024, 25 (01)
12345